CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?

Cancer Statistics, 2017.

Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712 · see citing works

Cancer nanomedicine: progress, challenges and opportunities

Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · see citing works

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,780 · see citing works

Drug Delivery Systems: Entering the Mainstream

Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · see citing works

Acute Myeloid Leukemia

Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,354 · see citing works

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,348 · see citing works

The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting

Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495 · see citing works

Age and acute myeloid leukemia

Appelbaum, F. R., Gundacker, H. M., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,352 · see citing works

Holland-Frei Cancer Medicine

(2016) · Wiley eBooks · doi:10.1002/9781119000822 · Cited by 1,151 · see citing works

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

Juliusson, G., Antunović, P., Derolf, Å. R., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wåhlin, A., & Höglund, M. (2008) · Blood · doi:10.1182/blood-2008-07-172007 · Cited by 991 · see citing works

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

Grimwade, D. J. (2001) · Blood · doi:10.1182/blood.v98.5.1312 · Cited by 917 · see citing works

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

Leith, C. P., Kopecky, K. J., Godwin, J. E., McConnell, T. S., Slovak, M. L., Chen, I.-M., Head, D. R., Appelbaum, F. R., & Willman, C. L. (1997) · Blood · doi:10.1182/blood.v89.9.3323 · Cited by 859 · see citing works

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J. A., Jongen‐Lavrencic, M., von Lilienfeld‐Toal, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901409 · Cited by 828 · see citing works

Targeted pharmaceutical nanocarriers for cancer therapy and imaging

Torchilin, V. P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902015 · Cited by 758 · see citing works

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608 · see citing works

A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]

Bishop, J., Matthews, J., Young, G. A. R., Szer, J., Gillett, A., Joshua, D., Bradstock, K. F., Enno, A., Wolf, M., & Fox, R. M. (1996) · Blood · doi:10.1182/blood.v87.5.1710.1710 · Cited by 458 · see citing works

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., & Clark, R. E. (2001) · Blood · doi:10.1182/blood.v98.5.1302 · Cited by 437 · see citing works

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

Jk, W., Kopecky, K., Appelbaum, F. R., Head, D., Kingsbury, L., Sp, B., Bickers, J., Hynes, H., Welborn, J., Simon, S. R., et al. (1996) · Blood · doi:10.1182/blood.v88.8.2841.bloodjournal8882841 · Cited by 411 · see citing works

Targeted drug delivery via folate receptors

Zhao, X. B., Li, H., & Lee, R. J. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.3.309 · Cited by 358 · see citing works

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy

Tardi, P. G., Johnstone, S. A., Harasym, N. L., Xie, S., Harasym, T. O., Zisman, N., Harvie, P., Bermudes, D. G., & Mayer, L. D. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.028 · Cited by 357 · see citing works

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

Lancet, J. E., Cortes, J. E., Hogge, D. E., Tallman, M. S., Kovacsovics, T. J., Damon, L. E., Komrokji, R. S., Solomon, S. R., Kolitz, J. E., Cooper, M. A., et al. (2014) · Blood · doi:10.1182/blood-2013-12-540971 · Cited by 339 · see citing works

Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

Mayer, L. D., Harasym, T. O., Tardi, P. G., Harasym, N. L., Shew, C. R., Johnstone, S. A., Ramsay, E. C., Bally, M. B., & Janoff, A. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0118 · Cited by 332 · see citing works

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461

Farag, S. S., Archer, K. J., Mrózek, K., Ruppert, A. S., Carroll, A. J., Vardiman, J. W., Pettenati, M. J., Baer, M. R., Qumsiyeh, M. Β., Koduru, P. R. K., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4354 · Cited by 332 · see citing works

Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.

Büchner, T., Hiddemann, W., Wormann, B. J., Löffler, H., Gassmann, W., Haferlach, T., Fonatsch, C., Haase, D. T., Schoch, C., Hossfeld, D. K., et al. (1999) · PubMed · doi:10.1182/blood.v93.12.4116 · Cited by 317 · see citing works

Immunophenotyping of leukemias using a cluster of differentiation antibody microarray.

Belov, L., de la Vega, O., dos Remedios, C. G., Mulligan, S. P., & Christopherson, R. I. (2001) · PubMed · Cited by 317 · see citing works

Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress

Dong, X., & Mumper, R. J. (2010) · Nanomedicine · doi:10.2217/nnm.10.35 · Cited by 314 · see citing works

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Feldman, E. J., Lancet, J. E., Kolitz, J. E., Ritchie, E. K., Roboz, G. J., List, A. F., Allen, S. L., Asatiani, E., Mayer, L. D., Swenson, C. E., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5961 · Cited by 310 · see citing works

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B

Fröhling, S., Schlenk, R. F., Käyser, S., Morhardt, M., Benner, A., Döhner, K., Döhner, H., & for the German-Austrian AML Study Group (2006) · Blood · doi:10.1182/blood-2006-04-014324 · Cited by 300 · see citing works

Chronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., Curtin, P., DeAngelo, D. J., Gotlib, J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0071 · Cited by 277 · see citing works

Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group

Bishop, J., Lowenthal, R., Joshua, D., Matthews, J., Todd, D., Cobcroft, R., Whiteside, M. G., KRONENBERG, H., Ma, D. D. F., & Dodds, A. J. (1990) · Blood · doi:10.1182/blood.v75.1.27.27 · Cited by 267 · see citing works

Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Bose, P., Vachhani, P. J., & Cortes, J. E. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0456-2 · Cited by 239 · see citing works

Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells.

He, S., Fm, S., & Wilcox, W. S. (1967) · PubMed · Cited by 233 · see citing works

Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome

Estey, E. H., Thall, P. F., Pierce, S. A., Cortes, J. E., Beran, M., Kantarjian, H. M., Keating, M. J., Andreeff, M., & Freireich, E. J. (1999) · Blood · doi:10.1182/blood.v93.8.2478.408k04_2478_2484 · Cited by 224 · see citing works

Optimizing Combination Chemotherapy by Controlling Drug Ratios

Mayer, L. D., & Janoff, A. S. (2007) · Molecular Interventions · doi:10.1124/mi.7.4.8 · Cited by 214 · see citing works

Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.

Jabbour, E. J., Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2005) · Blood · doi:10.1182/blood.v106.11.1846.1846 · Cited by 183 · see citing works

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1990 · Cited by 183 · see citing works

Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

Cortes, J. E., Goldberg, S. L., Feldman, E. J., Rizzeri, D. A., Hogge, D. E., Larson, M., Pigneux, A., Recher, C., Schiller, G., Warzocha, K., et al. (2015) · Cancer · doi:10.1002/cncr.28974 · Cited by 175 · see citing works

Comparison of idarubicin + ara-C–, fludarabine + ara-C–, and topotecan + ara-C–based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

Estey, E. H., Thall, P. F., Cortes, J. E., Giles, F. J., O'Brien, S. M., Pierce, S. A., Wang, X., Kantarjian, H. M., & Beran, M. (2001) · Blood · doi:10.1182/blood.v98.13.3575 · Cited by 164 · see citing works

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts

Lim, W.-S., Tardi, P. G., Santos, N. D., Xie, X., Fan, M., Liboiron, B. D., Huang, X., Harasym, T. O., Bermudes, D. G., & Mayer, L. D. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.01.015 · Cited by 164 · see citing works

Final results of a phase III randomized trial of CPX-351 versus 7+ 3 in older patients with newly diagnosed high risk (secondary) AML

Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7000 · Cited by 164 · see citing works

The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])

Stone, R. M., Mandrekar, S. J., Sanford, B. L., Geyer, S. M., Bloomfield, C. D., Döhner, K., Thiede, C., Marcucci, G., Lo‐Coco, F., Klisovic, R. B., et al. (2015) · Blood · doi:10.1182/blood.v126.23.6.6 · Cited by 159 · see citing works

High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results.

Wolff, S. N., Herzig, R. H., Fay, J. W. J., Phillips, G. L., Lazarus, H. M., Flexner, J. M., Stein, R. S., Greer, J. P., Cooper, B., & Herzig, G. P. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1260 · Cited by 143 · see citing works

How I treat older patients with AML

Estey, E. H. (2000) · Blood · doi:10.1182/blood.v96.5.1670.h8001670a_1670_1673 · Cited by 108 · see citing works

How I treat older patients with AML

Estey, E. H. (2000) · Blood · doi:10.1182/blood.v96.5.1670 · Cited by 101 · see citing works

Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells

Banker, D. E., Mayer, S. J., Li, H. Y., Willman, C. L., Appelbaum, F. R., & Zager, R. A. (2004) · Blood · doi:10.1182/blood-2004-01-0395 · Cited by 100 · see citing works

Immunological classification of acute myeloblastic leukemias: relevance to patient outcome

Casasnovas, O., Slimane, F. K. R., Garand, R., Faure, G. C., Campos, L., Deneys, V., Bernier, M., Falkenrodt, A., Calvez, G. L., Maynadié, M., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402821 · Cited by 96 · see citing works

Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells

Kim, H. P., Gerhard, B., Harasym, T. O., Mayer, L. D., & Hogge, D. E. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.04.001 · Cited by 87 · see citing works

Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin

Dicko, A., Kwak, S., Frazier, A. A., Mayer, L. D., & Liboiron, B. D. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.02.014 · Cited by 87 · see citing works

LIPOSOMAL DAUNORUBICIN OVERCOMES DRUG RESISTANCE IN HUMAN BREAST, OVARIAN AND LUNG CARCINOMA CELLS

Sadava, D., Coleman, A., & Kane, S. E. (2002) · Journal of Liposome Research · doi:10.1081/lpr-120016196 · Cited by 63 · see citing works

Effect of liposomes on P-glycoprotein function in multidrug resistant cells

Thierry, A. R., Dritschilo, A., & Rahman, A. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91310-m · Cited by 62 · see citing works

Treatment of newly‐diagnosed acute myelogenous leukaemia in patients aged 80 years and above

Lima, M. J. G. D., Ghaddar, H. M., Pierce, S. A., & Estey, E. H. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.4771012.x · Cited by 62 · see citing works

Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and −5/5q−

Middeke, J. M., Beelen, D. W., Stadler, M., Göhring, G., Schlegelberger, B., Baurmann, H., Bug, G., Bellos, F., Mohr, B., Buchholz, S., et al. (2012) · Blood · doi:10.1182/blood-2012-03-417972 · Cited by 59 · see citing works

Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants

Pavillard, V., Kherfellah, D., Richard, S., Robert, J., & Montaudon, D. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2027 · Cited by 59 · see citing works

Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients

Robert, J., Rigal‐Huguet, F., & Hurteloup, P. (1992) · Hematological Oncology · doi:10.1002/hon.2900100207 · Cited by 58 · see citing works

Increased accumulation of drugs in multidrug-resistant cells induced by liposomes.

Warren, L., Jardillier, J. C., Malarska, A., & Akeli, M. G. (1992) · PubMed · Cited by 56 · see citing works

Application of theoretical models to chemotherapy protocol design.

Goldie, J. H., & Coldman, A. J. (1986) · PubMed · Cited by 56 · see citing works

Role of Formulation Composition in Folate Receptor-Targeted Liposomal Doxorubicin Delivery to Acute Myelogenous Leukemia Cells

Lu, Y., Wu, J. H., Wu, J., Gonit, M., Yang, X., Lee, A., Xiang, G., Li, H., Liu, S., Marcucci, G., et al. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070058l · Cited by 52 · see citing works

Chemotherapy resistance in acute myeloid leukaemia

Sonneveld, P., & List, A. F. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2000.0124 · Cited by 50 · see citing works

Combination therapy with 5-fluorouracil and L-canavanine

Swaffar, D. S., Ang, C. Y., Desai, P. B., Rosenthal, G. A., Thomas, D. A., Crooks, P. A., & John, W. J. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199508000-00012 · Cited by 48 · see citing works

The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status

Díaz‐Beyá, M., Rozman, M., Pratcorona, M., Torrebadell, M., Camós, M., Aguilar, J. L., & Esteve, J. (2010) · Blood · doi:10.1182/blood-2010-09-307314 · Cited by 46 · see citing works

The Role for Liposomal Drug Delivery in Molecular and Pharmacological Strategies to Overcome Multidrug Resistance

Mayer, L. D., & Shabbits, J. A. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013108524062 · Cited by 39 · see citing works

Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation

Xu, Y., McKenna, R. W., Wilson, K. S., Karandikar, N. J., Schultz, R. A., & Kroft, S. H. (2006) · Leukemia · doi:10.1038/sj.leu.2404242 · Cited by 35 · see citing works

Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study

Fleming, R. A., Capizzi, R. L., Rosner, G. L., Oliver, L. K., Smith, S. J., Schiffer, C. A., Silver, R. T., Peterson, B. A., Weiss, R. B., OMURA, G. A., et al. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686192 · Cited by 34 · see citing works

Principles of Dose, Schedule, and Combination Therapy

Hait, W. N., & Eder, J. P. (2019) · Wiley eBooks · doi:10.1002/9781119000822.hfcm055.pub2 · Cited by 32 · see citing works

Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts

Lim, W.-S., Tardi, P. G., Xie, X., Fan, M., Huang, R. Y., Ciofani, T., Harasym, T. O., & Mayer, L. D. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.490312 · Cited by 30 · see citing works

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation

Gordon, M. J., Tardi, P. G., Loriaux, M., Spurgeon, S. E. F., Traer, E. A., Kovacsovics, T. J., Mayer, L. D., & Tyner, J. W. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.12.002 · Cited by 25 · see citing works

Efficacy of CPX‐351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program

Carol, H., Fan, M., Harasym, T. O., Boehm, I., Mayer, L. D., Houghton, P. J., Smith, M. A., & Lock, R. B. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25133 · Cited by 23 · see citing works

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

Lancet, J. E., Hoering, A., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D. E., et al. (2016) · Blood · doi:10.1182/blood.v128.22.906.906 · Cited by 20 · see citing works

A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia

Gergis, U. S., Roboz, G. J., Shore, T. B., Ritchie, E. K., Mayer, S. A., Wissa, U., McKenna, M., Christos, P. J., Pearse, R. N., Mark, T. M., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.04.013 · Cited by 18 · see citing works

A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis

Minakata, D., Fujiwara, S., Ito, S., Mashima, K., Umino, K., Nakano, H., Kawasaki, Y., Sugimoto, M., Yamasaki, R., Yamamoto, C., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2015.12.013 · Cited by 14 · see citing works

The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.

Sauvage, F., BARRATT, G. M., Herfindal, L., & Vergnaud, J. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150817095045 · Cited by 12 · see citing works

Effects of daunorubicin on cell growth, cell cycle and induction of apoptosis in HL-60 cells.

Chikayama, S., Kimura, S. H., Kobayashi, Y., Abe, T., Maekawa, T., & Kondo, M. (1998) · PubMed · Cited by 10 · see citing works

Targeting Notch-1 positive acute leukemia cells by novel fucose-bound liposomes carrying daunorubicin

Ono, M., Takimoto, R., Osuga, T., Okagawa, Y., Hirakawa, M., Yoshida, M., Arihara, Y., Uemura, N., Hayasaka, N., Miura, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9558 · Cited by 10 · see citing works

Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Lancet, J., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D. E., Solomon, S. R., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.12.090 · Cited by 5 · see citing works

Smart nanoparticles for cancer therapy

Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073 · see citing works

Treatment of MDS

Platzbecker, U. (2019) · Blood · doi:10.1182/blood-2018-10-844696 · Cited by 237 · see citing works

Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy

Zhai, B., Zeng, Y., Zeng, Z., Zhang, N., Li, C., Zeng, Y., You, Y., Wang, S., Chen, X., Sui, X., et al. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s174527 · Cited by 157 · see citing works

Clinical applications of nanomedicine in cancer therapy

Norouzi, M., Amerian, M., Amerian, M., & Atyabi, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.017 · Cited by 126 · see citing works

Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments

Pusuluri, A., Wu, D., & Mitragotri, S. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.020 · Cited by 69 · see citing works

An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia

Zheng, B., Yu, S., Rosario, G. D., Leong, S. R., Lee, G. Y., Vij, R., Chiu, C., Liang, W., Wu, Y. P., Chalouni, C. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0333 · Cited by 66 · see citing works

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options

Iurlo, A., Cattaneo, D., & Gianelli, U. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081839 · Cited by 59 · see citing works

Design principles of drug combinations for chemotherapy

Wu, D., Pusuluri, A., Vogus, D. R., Krishnan, V., Shields, C. W., Kim, J., Razmi, A. N., & Mitragotri, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.018 · Cited by 52 · see citing works

Advances in treatment formulations for acute myeloid leukemia

Briot, T., Roger, E., Thépot, S., & Lagarce, F. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.040 · Cited by 50 · see citing works

The leukemia strikes back: a review of pathogenesis and treatment of secondary AML

Cheung, E., Perissinotti, A. J., Bixby, D. L., Burke, P. W., Pettit, K. M., Benitez, L. L., Brown, J. M., Scappaticci, G. B., & Marini, B. L. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03606-0 · Cited by 48 · see citing works

Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy

Wang, W., & Tse‐Dinh, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190401113350 · Cited by 35 · see citing works

How to address second and therapy‐related acute myelogenous leukaemia

Oliai, C. H., & Schiller, G. J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16354 · Cited by 23 · see citing works

Health state utilities associated with treatment options for acute myeloid leukemia (AML)

Matza, L. S., Deger, K. A., Howell, T. A., Koetter, K., Yeager, A. M., Hogge, D. E., Fisher, V. L., Louie, A. C., & Chung, K. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1584108 · Cited by 15 · see citing works

Tumor in 3D: In Vitro Complex Cellular Models to Improve Nanodrugs Cancer Therapy

Fernandes, S., Cassani, M., Pagliari, S., Filipenský, P., Cavalieri, F., & Forte, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200625151134 · Cited by 14 · see citing works

An overview of randomized phase III clinical trials of cancer nanomedicines

Melo, M. N., Amaral, R. G., de Andrade, L. R. M., Severino, P. B., Blanco-Llamero, C., Andrade, L. N., & Souto, E. B. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.10.001 · Cited by 13 · see citing works

Oncology stewardship in acute myeloid leukemia

Ochs, M. A., Marini, B. L., Perissinotti, A. J., Foucar, C. E., Pettit, K. M., Burke, P. W., Bixby, D. L., & Benitez, L. L. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04872-1 · Cited by 11 · see citing works

Synchronized Codelivery of Combination Chemotherapies Intratumorally Using a Lipidic Lyotropic Liquid Crystal System

Saklani, R., Yadav, P. K., Tiwari, A. K., Gawali, S. L., Hassan, P. A., Yadav, K. S., Mugale, M. N., Kalleti, N., Rath, S. K., Mishra, D. P., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c01432 · Cited by 8 · see citing works

Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?

Tarantini, F., Cumbo, C., Anelli, L., Zagaria, A., Specchia, G., Musto, P., & Albano, F. (2021) · Cancers · doi:10.3390/cancers13164121 · Cited by 7 · see citing works

CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML

Anderson, E., Mehta, P., Heywood, J., Rees, B., Bone, H. K., Robinson, G. M., Reynolds, D. M., Salisbury, V. C., & Mayer, L. D. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.08.007 · Cited by 5 · see citing works

Liposomal Cytarabine–Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review

Howell, G., Oliai, C. H., & Schiller, G. J. (2018) · Anticancer Research · doi:10.21873/anticanres.13070 · Cited by 4 · see citing works

Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia

Asghari, H. H., & Lancet, J. E. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1719093 · Cited by 3 · see citing works

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial

Oliai, C. H., Park, S., Damon, L. E., Jonas, B. A., Jeyakumar, D., Wieduwilt, M. J., Logan, A. C., Callas, B., Hannigan, C. A., Gaut, D. L., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2438809 · Cited by 1 · see citing works

Cd44 Targeted Plga Nano-Medicine For Cancer Chemotherapy- A Comprehensive Review

Kumar, R., Sunıta, J. H. A., & Rai, A. (2023) · Journal of Immunology and Clinical Microbiology · doi:10.58854/jicm.1315037 · Cited by 1 · see citing works

CPX-351 and the Frontier of Nanoparticle-Based Therapeutics in Acute Myeloid Leukemia

Konstantinidis, I. K., Tsokkou, S., Keramas, A., Gavriilaki, E., Delis, G. A., & Papamitsou, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311628 · Cited by 1 · see citing works

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML

Molica, M., Perrone, S., Mazzone, C., Cesini, L., Canichella, M., & de Fabritiis, P. (2022) · Cancers · doi:10.3390/cancers14122843 · Cited by 14 · see citing works

CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia

Thomas, X., & Pleșa, A. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00145-9 · Cited by 3 · see citing works

CPX-351: Changing the Landscape of Treatment for Patients with Secondary Acute Myeloid Leukemia

Talati, C., & Lancet, J. E. (2018) · Future Oncology · doi:10.2217/fon-2017-0603 · Cited by 19 · see citing works

Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia

Ronson, A., Tvito, A., & Rowe, J. M. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1256768 · Cited by 2 · see citing works